COMPANY
AltruBio
Based on the structure of ALTB-168, we have developed ALTB-268, a second-generation antibody with tetravalent design, which has demonstrated improved potency in a pre-clinical setting. From company website Source · Oct 12, 2026
Timeline
- Trial start Phase 1: Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants source ↗
- Trial start Phase 2: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics source ↗
- Trial start Phase 1: A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers source ↗
- Trial start Phase 1: Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease source ↗
- Trial start Phase 2: Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC source ↗
Clinical trials (lead sponsor) 5
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06109441 | Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics | Phase 2 | Active, not recruiting | Dec 4, 2023 | Mar 5, 2026 (actual) |
| NCT07350577 | Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants | Phase 1 | Active, not recruiting | Nov 17, 2025 | Sep 26, 2026 (estimated) |
| NCT05723692 | A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers | Phase 1 | Completed | Jan 17, 2023 | Oct 27, 2023 (actual) |
| NCT03298022 | Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC | Phase 2 | Terminated | May 4, 2018 | Apr 6, 2020 (actual) |
| NCT03327857 | Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease | Phase 1 | Completed | May 31, 2018 | Sep 30, 2022 (actual) |